Monophasic Oral Contraceptive Pills

Introduction to Monophasic OCPs

The American Academy of Pediatrics recommends monophasic oral contraceptive pills (OCPs) as the preferred initial choice for most patients due to their consistent hormone delivery and well-established efficacy profiles 1, 2

Monophasic OCPs contain the same dose of estrogen and progestin in each active tablet, typically with 21-24 hormone pills and 4-7 placebo pills in a 28-day pack 1
Fixed-dose monophasic regimens are available, containing 30-35 μg of ethinyl estradiol and a progestin such as levonorgestrel 1

Many experts recommend starting adolescents on a monophasic pill with monthly bleeding and then changing regimens as needed to address adverse effects or patient preference 1
Monophasic OCPs can be used in standard 28-day cycles or in extended/continuous regimens, which may be particularly appropriate for patients with conditions like anemia, severe dysmenorrhea, endometriosis, or abnormal uterine bleeding 2, 3, 1
The most common adverse effect of extended-cycle regimens is unscheduled bleeding 1

Modern monophasic OCPs typically contain ≤50 μg of ethinyl estradiol combined with second, third, or fourth generation progestins, which were developed to reduce cardiovascular risks associated with earlier higher-dose pills 2, 3
Blood pressure should be assessed before initiating any OCP, as estrogen-containing contraceptives can increase blood pressure in some users 3
The baseline risk of venous thromboembolism in adolescents is approximately 1 per 10,000 woman-years, with combined OCPs increasing this risk three to fourfold 4